Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03736850 | Completed Phase 1

• 1 other identifier: CS3006-102
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, open label, sequential-cohort, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD）, if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.

Conditions

Locally Advanced or Metastatic Solid Tumors

Outcome Measures

Primary Outcomes (1)

• Number of participants with adverse events

  From the day of first dose to 30 days after last dose of CS3006

Study Arms (1)

CS3006

EXPERIMENTAL

Drug: CS3006

Interventions

CS3006 DRUG

In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, participants will receive CS3006 at specified dose level(s).

CS3006

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to provide written informed consent for the trial.
• Subjects must have a histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Life expectancy ≥ 12 weeks.
• Able to swallow and retain oral medication.
• Subject must have adequate organ function.
• Use of effective contraception.

You may not qualify if:

• Subjects receiving cancer therapy at the time of enrollment.
• Has had prior chemotherapy, targeted therapy, immunotherapy or any other agents used as systemic treatment for cancer, within 14 days of the first dose of investigational product administration or who has not recovered from adverse events due to a previously administered agent.
• Previous treatment with a MEK inhibitor.
• Use of any investigational anti-cancer drug within 28 days before the first investigational product administration.
• Current use of a prohibited medication.
• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
• Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.
• Primary malignancy of the central nervous system.
• Evidence of severe or uncontrolled systemic diseases.
• Subjects with clinically significant cardiovascular disease.
• Human Immunodeficiency Virus (HIV) infection.
• Subjects with active Hepatitis B or C infection.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product or excipients.
• Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.
• Unwillingness or inability to follow the procedures outlined in the protocol.

Sponsors & Collaborators

• CStone Pharmaceuticals: lead

Study Sites (1)

People's Liberation Army 307 Hospital

Beijing, Beijing Municipality, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2018
• First Posted: November 9, 2018
• Study Start: October 19, 2018
• Primary Completion: May 15, 2020
• Study Completion: May 15, 2020
• Last Updated: January 12, 2021

Record last verified: 2020-03

Locations

CN (1)